NCT 03391869 (LONESTAR) Randomized Phase III Trial of Local Consolidation Therapy After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients with Metastatic Non-Small Cell Lung Cancer -Strategic Alliance: BMS. Primary outcome measure is overall survival. Estimated enrollment is 270 patients.